Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Immunornase Therapy Of Lymphoma With Novel CD22-Targeting Quadruple Ranpirnase

Donglin Liu, Ph.D., Thomas M Cardillo, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2013) 122 (21): 3075.

https://doi.org/10.1182/blood.V122.21.3075.3075

Published: 2013

Journal Articles

A New Platform For Trivalent Bispecific Antibodies Used For T-Cell Redirected Killing Of B-Cell Malignancies

Diane L Rossi, M.S., Edmund A Rossi, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2013) 122 (21): 3078.

https://doi.org/10.1182/blood.V122.21.3078.3078

Published: 2013

Journal Articles

Bispecific Hexavalant Antibodies With Enhanced Trogocytosis For Treatment Of Lupus

Edmund A Rossi, Ph.D, Rosana Michel, M.S., Chien-Hsing Chang, Ph.D, David M Goldenberg, ScD, MD

Blood (2013) 122 (21): 2282.

https://doi.org/10.1182/blood.V122.21.2282.2282

Published: 2013

Journal Articles

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab

Edmund A. Rossi, David M. Goldenberg, Rosana Michel, Diane L. Rossi, Daniel J. Wallace, Chien-Hsing Chang

Blood (2013) 122 (17): 3020–3029.

https://doi.org/10.1182/blood-2012-12-473744

Published: 2013

Includes: Supplemental data

Journal Articles

A New Class of Hexavalent Bispecific Antibodies and Immunocytokines with Enhanced Pharmacokinetics and Improved Efficacy in Vivo .

Edmund A Rossi, Ph.D, Thomas M Cardillo, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2012) 120 (21): 2451.

https://doi.org/10.1182/blood.V120.21.2451.2451

Published: 2012

Journal Articles

CD22-Targeting Epratuzumab Down-Regulates Multiple BCR Regulators On the Surface of Normal, Lupus, and Malignant B Cells

Edmund A Rossi, Ph.D, Rosana Michel, M.S., Daniel J Wallace, MD, Chien-Hsing Chang, Ph.D, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 1357.

https://doi.org/10.1182/blood.V120.21.1357.1357

Published: 2012

Journal Articles

Prevention of Acute Graft-Versus-Host Disease in Human/Mouse Xenogeneic SCID Mouse Model by Humanized Anti-CD74 Monoclonal Antibody, Milatuzumab

Xiaochuan Chen, Ph.D, Chien-Hsing Chang, Ph.D, Rhona Stein, Ph.D, Thomas M Cardillo, Ph.D, David V. Gold, Ph.D., David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 4105.

https://doi.org/10.1182/blood.V120.21.4105.4105

Published: 2012

Journal Articles

A Novel T-Cell Redirecting Anti-CD19-F(ab) 2 /CD3scFv Bispecific Antibody Exhibits Potent Lymphoma Cytotoxicity.

Diane L Rossi, M.S., Edmund A Rossi, Ph.D, Thomas M Cardillo, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2012) 120 (21): 2762.

https://doi.org/10.1182/blood.V120.21.2762.2762

Published: 2012

Journal Articles

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

Pankaj Gupta, David M. Goldenberg, Edmund A. Rossi, Thomas M. Cardillo, John C. Byrd, Natarajan Muthusamy, Richard R. Furman, Chien-Hsing Chang

Blood (2012) 119 (16): 3767–3778.

https://doi.org/10.1182/blood-2011-09-381988

Published: 2012

Includes: Supplemental data

Journal Articles

Combination Therapy with FTY720 (Fingolimod) and Bispecific Anti-CD20/CD74 Antibodies in Mantle Cell Lymphoma,

Pankaj Gupta, Ph.D, Rosana Michel, M.S., David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2011) 118 (21): 3736.

https://doi.org/10.1182/blood.V118.21.3736.3736

Published: 2011

Journal Articles

Juxtaposing CD20 and CD74 with Novel Bispecific Antibodies Evokes Potent Cytotoxicity in Mantle Cell Lymphoma (MCL)

Pankaj Gupta, Ph.D, David M. Goldenberg, ScD, MD, Edmund A Rossi, Ph.D, Thomas M. Cardillo, Ph.D, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D, Richard R. Furman, MD, Chien-Hsing Chang, Ph.D

Blood (2011) 118 (21): 599.

https://doi.org/10.1182/blood.V118.21.599.599

Published: 2011

Journal Articles

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers

Edmund A. Rossi, Diane L. Rossi, Thomas M. Cardillo, Rhona Stein, David M. Goldenberg, Chien-Hsing Chang

Blood (2011) 118 (7): 1877–1884.

https://doi.org/10.1182/blood-2011-03-343145

Published: 2011

Includes: Supplemental data

Journal Articles

Depletion of Blood Antigen-Presenting Cells by IMMU-114: Therapeutic Potential Against Graft-Versus-Host Disease

Xiaochuan Chen, Chien-Hsing Chang, Rhona Stein, David Goldenberg

Blood (2010) 116 (21): 2544.

https://doi.org/10.1182/blood.V116.21.2544.2544

Published: 2010

Journal Articles

Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias

Pankaj Gupta, David M. Goldenberg, Edmund A. Rossi, Chien-Hsing Chang

Blood (2010) 116 (17): 3258–3267.

https://doi.org/10.1182/blood-2010-03-276857

Published: 2010

Journal Articles

Therapy of B-cell malignancies by anti–HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

Rhona Stein, Pankaj Gupta, Xiaochuan Chen, Thomas M. Cardillo, Richard R. Furman, Susan Chen, Chien-Hsing Chang, David M. Goldenberg

Blood (2010) 115 (25): 5180–5190.

https://doi.org/10.1182/blood-2009-06-228288

Published: 2010

Includes: Supplemental data

Journal Articles

First Bispecific Antibody Immunocytokine (Anti-CD20/HLA-DR-Interferon-á2b) Is Highly Toxic for Human Lymphoma Cells in Vitro .

Diane L Nordstrom, Edmund A Rossi, PhD, David M. Goldenberg, ScD, MD, Chien-Hsing Chang, PhD

Blood (2009) 114 (22): 1695.

https://doi.org/10.1182/blood.V114.22.1695.1695

Published: 2009

Journal Articles

Therapy of B-Cell Malignancies by Anti-HLA-DR Humanized Monoclonal Antibody, IMMU-114, Is Mediated through Hyperactivation of ERK and JNK MAP Kinase Signaling Pathways.

Pankaj Gupta, Ph.D, Rhona Stein, PhD, Thomas M Cardillo, PhD, Richard R Furman, Susan Chen, Chien-Hsing Chang, PhD, David M. Goldenberg, ScD, MD

Blood (2009) 114 (22): 3738.

https://doi.org/10.1182/blood.V114.22.3738.3738

Published: 2009

Journal Articles

A Novel Ribonuclease-Based Immunotoxin Comprising Quadruple Ranpirnase (Rap) Site-Specifically Conjugated to An Anti-CD22 IgG Showing Potent Anti-Lymphoma Activity.

Edmund A Rossi, PhD, Eric Chan, Pankaj Gupta, Ph.D, David M. Goldenberg, ScD, MD, Chien-Hsing Chang, PhD

Blood (2009) 114 (22): 3721.

https://doi.org/10.1182/blood.V114.22.3721.3721

Published: 2009

Journal Articles

Differential Effects of Milatuzumab On Human Antigen-Presenting Cells in Comparison to Malignant B Cells.

Xiaochuan Chen, Ph.D., Rhona Stein, PhD, Chien-Hsing Chang, PhD, David M. Goldenberg, ScD, MD

Blood (2009) 114 (22): 2744.

https://doi.org/10.1182/blood.V114.22.2744.2744

Published: 2009

Journal Articles

CD20-targeted tetrameric interferon-α, a novel and potent immunocytokine for the therapy of B-cell lymphomas

Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo, Rhona Stein, Chien-Hsing Chang

Blood (2009) 114 (18): 3864–3871.

https://doi.org/10.1182/blood-2009-06-228890

Published: 2009

Includes: Supplemental data

NARROW

Immunornase Therapy Of Lymphoma With Novel CD22-Targeting Quadruple Ranpirnase

A New Platform For Trivalent Bispecific Antibodies Used For T-Cell Redirected Killing Of B-Cell Malignancies

Bispecific Hexavalant Antibodies With Enhanced Trogocytosis For Treatment Of Lupus

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab

A New Class of Hexavalent Bispecific Antibodies and Immunocytokines with Enhanced Pharmacokinetics and Improved Efficacy in Vivo .

CD22-Targeting Epratuzumab Down-Regulates Multiple BCR Regulators On the Surface of Normal, Lupus, and Malignant B Cells

Prevention of Acute Graft-Versus-Host Disease in Human/Mouse Xenogeneic SCID Mouse Model by Humanized Anti-CD74 Monoclonal Antibody, Milatuzumab

A Novel T-Cell Redirecting Anti-CD19-F(ab) 2 /CD3scFv Bispecific Antibody Exhibits Potent Lymphoma Cytotoxicity.

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

Combination Therapy with FTY720 (Fingolimod) and Bispecific Anti-CD20/CD74 Antibodies in Mantle Cell Lymphoma,

Juxtaposing CD20 and CD74 with Novel Bispecific Antibodies Evokes Potent Cytotoxicity in Mantle Cell Lymphoma (MCL)

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers

Depletion of Blood Antigen-Presenting Cells by IMMU-114: Therapeutic Potential Against Graft-Versus-Host Disease

Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias

Therapy of B-cell malignancies by anti–HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

First Bispecific Antibody Immunocytokine (Anti-CD20/HLA-DR-Interferon-á2b) Is Highly Toxic for Human Lymphoma Cells in Vitro .

Therapy of B-Cell Malignancies by Anti-HLA-DR Humanized Monoclonal Antibody, IMMU-114, Is Mediated through Hyperactivation of ERK and JNK MAP Kinase Signaling Pathways.

A Novel Ribonuclease-Based Immunotoxin Comprising Quadruple Ranpirnase (Rap) Site-Specifically Conjugated to An Anti-CD22 IgG Showing Potent Anti-Lymphoma Activity.

Differential Effects of Milatuzumab On Human Antigen-Presenting Cells in Comparison to Malignant B Cells.

CD20-targeted tetrameric interferon-α, a novel and potent immunocytokine for the therapy of B-cell lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only